Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
PharmaShots
Beyond Clinical Trials: AbbVie’s Julie Adams, Roger McIntyre, and Andrew Cutler on VRAYLAR’s Real-World Impact
Shots: Saurabh: Real-world evidence can reveal how a therapy performs beyond the controlled environment of clinical trials. What do the latest CReW BP-I and ProACt findings reveal about the effectiveness of VRAYLAR in everyday clinical practice?  Julie: The findings from these prospective real-world studies show that VRAYLAR (cariprazine) improves depressive symptoms, functioning, and quality of… The post Beyond Clinical Trials: AbbVie’s Julie Adams, Roger McIntyre, and Andrew Cutler on VRAYLAR’s Real-World Impact appeared first on PharmaShots.
Read Full Article
Pharma Tech
MHRA could allow schools to hold reserves of nasal adrenaline spray
Though schools already store autoinjectors like EpiPen, a nasal spray would offer another easy-to-use option.
Read Full Article
Pharma Tech
FDA approves Viatris’ Ryzumvi for adult presbyopia
The US FDA has approved Viatris' Ryzumvi (phentolamine ophthalmic solution 0.75%) to treat presbyopia in adults.
Read Full Article
Express Pharma
Alembic Pharma gets USFDA nod for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%
According to IQVIA, the estimated market size for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%, was $110 million for twelve months ending June 2026 The post Alembic Pharma gets USFDA nod for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1% appeared first on Express Pharma.
Read Full Article
Express Pharma
NPPA caps trade margins at 30 per cent for 137 anti-cancer medicines
Industry associations like IPA and OPPI welcomes the move; but highlight the need to ensure affordability and uninterrupted availability The post NPPA caps trade margins at 30 per cent for 137 anti-cancer medicines appeared first on Express Pharma.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
PharmaShots
Oct 19, 2026, 3:16 PM
Merck KGaA to Acquire Silence Therapeutics for ~$1.3B to Strengthen Its Rare Disease Pipeline
Shots: Merck KGaA, Darmstadt, Germany has entered into a definitive agreement to acquire Silence Therapeutics, a UK-headquartered siRNA company, adding divesiran, a P-III-ready investigational siRNA therapy dosed SC once every 3mos. for phlebotomy-dependent polycythemia vera (PV), to its rare disease pipeline As per the deal, Merck KGaA will pay $20/ADS in cash (each ADS =… The post Merck KGaA to Acquire Silence Therapeutics for ~$1.3B to Strengthen Its Rare Disease Pipeline appeared first on PharmaShots.
PharmaShots
Oct 19, 2026, 3:05 PM
Hansoh Pharma and Roche Enter Over $15B Strategic Collaboration and License Agreement to Advance Novel ADC Portfolio
Shots: Hansoh Pharma has entered into a strategic collaboration & license agreement with Roche, marking their second ADC collaboration, to advance a broad ADC portfolio across multiple cancer types, comprising 2 preclinical Hansoh ADC programs & multiple ADC programs based on Roche-proposed targets powered by Hansoh’s proprietary ADC technology platform As per the deal, Hansoh… The post Hansoh Pharma and Roche Enter Over $15B Strategic Collaboration and License Agreement to Advance Novel ADC Portfolio appeared first on PharmaShots.
PharmaShots
Oct 19, 2026, 1:30 PM
Beyond Clinical Trials: AbbVie’s Julie Adams, Roger McIntyre, and Andrew Cutler on VRAYLAR’s Real-World Impact
Shots: Saurabh: Real-world evidence can reveal how a therapy performs beyond the controlled environment of clinical trials. What do the latest CReW BP-I and ProACt findings reveal about the effectiveness of VRAYLAR in everyday clinical practice?  Julie: The findings from these prospective real-world studies show that VRAYLAR (cariprazine) improves depressive symptoms, functioning, and quality of… The post Beyond Clinical Trials: AbbVie’s Julie Adams, Roger McIntyre, and Andrew Cutler on VRAYLAR’s Real-World Impact appeared first on PharmaShots.
PharmaShots
Oct 19, 2026, 11:48 AM
Gilead Reports P-II (SWIFT) Study Data of Emvistegrast for Moderately to Severely Active Ulcerative Colitis at UEGW 2026
Shots: Gilead has reported 12wk. placebo-controlled induction data from the dose-ranging P-II (SWIFT) study evaluating once-daily oral emvistegrast (GS-1427; 200mg, 75mg or 25mg) vs PBO in adults (aged 18–75yrs.) with moderately to severely active UC, presented as a late-breaking abstract at UEGW 2026 At Wk. 12, emvistegrast 200mg met the 1EP of clinical response (66%… The post Gilead Reports P-II (SWIFT) Study Data of Emvistegrast for Moderately to Severely Active Ulcerative Colitis at UEGW 2026 appeared first on PharmaShots.
PharmaShots
Oct 19, 2026, 11:48 AM
AbbVie Reports P-IIa (TARGET-CD) Data of ABBV-466 for Moderate to Severe Crohn’s Disease at UEGW 2026
Shots: AbbVie has reported data from the open-label, treat-through P-IIa platform (TARGET-CD) study of ABBV-466 (n=106) vs risankizumab (anti-IL-23 p19; n=94) or trosunilimab (anti-α4β7; n=100) monotherapy for 24wks. in pts (N=300) with moderately to severely active CD, of whom 75% had failed ≥1 advanced therapy; data were presented as a late-breaking abstract at UEGW 2026… The post AbbVie Reports P-IIa (TARGET-CD) Data of ABBV-466 for Moderate to Severe Crohn’s Disease at UEGW 2026 appeared first on PharmaShots.
PharmaShots
Oct 19, 2026, 11:48 AM
OSE Immunotherapeutics Reports Topline P-II (Combi-TED) Data of Tedopi (OSE2101) for Metastatic Non-Small Cell Lung Cancer
Shots: OSE Immunotherapeutics has released its ESMO 2026 abstract with topline results from the FoRT-sponsored, open-label, randomized, 3-arm P-II (Combi-TED) trial of Tedopi (OSE2101) + docetaxel or Tedopi + nivolumab vs docetaxel alone as 2L treatment in 106 HLA-A2+ pts with metastatic NSCLC (no EGFR mutation or ALK/ROS1 rearrangement) after 1L chemo-immunotherapy The trial met… The post OSE Immunotherapeutics Reports Topline P-II (Combi-TED) Data of Tedopi (OSE2101) for Metastatic Non-Small Cell Lung Cancer appeared first on PharmaShots.
News
Latest industry coverage
Google News
Oct 19, 2026, 8:12 PM
Asia-Pacific Roundup: Japan’s PMDA shares principles for evaluating generative AI-enabled medical devices - RAPS
Asia-Pacific Roundup: Japan’s PMDA shares principles for evaluating generative AI-enabled medical devices  RAPS
Google News
Oct 19, 2026, 8:09 PM
DHL expands cold chain network to improve healthcare shipping - FleetOwner
DHL expands cold chain network to improve healthcare shipping  FleetOwner
Google News
Oct 19, 2026, 8:05 PM
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors - Morningstar
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors  Morningstar
Google News
Oct 19, 2026, 8:05 PM
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors - PR Newswire
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors  PR Newswire
Google News
Oct 19, 2026, 8:05 PM
A drug candidate for heart problems linked to Duchenne muscular dystrophy will get an update - Stock Titan
A drug candidate for heart problems linked to Duchenne muscular dystrophy will get an update  Stock Titan
Google News
Oct 19, 2026, 7:59 PM
Recon: German Merck acquires Silence Therapeutics for $1.3B; China's Hansoh Pharma strikes $15B drug deal with Roche - RAPS
Recon: German Merck acquires Silence Therapeutics for $1.3B; China's Hansoh Pharma strikes $15B drug deal with Roche  RAPS
Google News
Oct 19, 2026, 7:53 PM
PacBio, Verily Health Ink Multi-Year Deal to Scale Multi-Read Genomic Data for Biomedical AI - Contract Pharma
PacBio, Verily Health Ink Multi-Year Deal to Scale Multi-Read Genomic Data for Biomedical AIÂ Â Contract Pharma
Google News
Oct 19, 2026, 7:05 PM
Cryoport Expands with BioServices Offering in Paris - Contract Pharma
Cryoport Expands with BioServices Offering in Paris  Contract Pharma
Google News
Oct 19, 2026, 7:05 PM
Merck KGaA to Acquire Silence Therapeutics, Adding siRNA Candidate to Pipeline - Contract Pharma
Merck KGaA to Acquire Silence Therapeutics, Adding siRNA Candidate to Pipeline  Contract Pharma
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer